Stem cell marker olfactomedin 4: Critical appraisal of its characteristics and role in tumorigenesis

Cancer and Metastasis Reviews

Volumn 29, Issue 4, 2010, Pages 761-775

  Grover, Phulwinder K ^a   Hardingham, Jennifer E ^a   Cummins, Adrian G ^a  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

Antiapoptotic; Cell cycle regulatory; Migratory; Mitotic; Olfactomedin 4; Tumorigenic

Indexed keywords

AMINO ACID; BETA CATENIN; COMPLEMENTARY DNA; GLYCOPROTEIN; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OLFACTOMEDIN 4; PROTEIN; RETINNOID INTERFERON INDUCED MORTALITY PROTEIN 19; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TUMOR MARKER; UNCLASSIFIED DRUG; WNT PROTEIN; OLFM4 PROTEIN, HUMAN;

AMINO ACID ANALYSIS; APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER STAGING; CARCINOGENESIS; CELL ADHESION; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL MIGRATION; CELL STRESS; COLON CANCER; COLORECTAL CARCINOMA; CPG ISLAND; DNA METHYLATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE MUTATION; GENE STRUCTURE; GENETIC TRANSDUCTION; HUMAN; LUNG CANCER; MITOSIS; MOLECULAR SIZE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; STEM CELL; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; UPREGULATION; WNT SIGNALING PATHWAY; CELL TRANSFORMATION; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY;

CELL TRANSFORMATION, NEOPLASTIC; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MODELS, MOLECULAR; STEM CELLS;

EID: 79952202070     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-010-9262-z     Document Type: Review

References (142)

1. Tomarev, S. I., & Nakaya, N. (2009). Olfactomedin domaincontaining proteins: possible mechanisms of action and functions in normal development and pathology. Molecular Neurobiology, 40(2), 122-138.
2. Bal, R. S., & Anholt, R. R. (1993). Formation of the extracellular mucous matrix of olfactory neuroepithelium: identification of partially glycosylated and nonglycosylated precursors of olfactomedin. Biochemistry, 32(4), 1047-1053. (Pubitemid 23057678)
3. Snyder, D. A., Rivers, A. M., Yokoe, H., Menco, B. P., & Anholt, R. R. (1991). Olfactomedin: purification, characterization, and localization of a novel olfactory glycoprotein. Biochemistry, 30(38), 9143-9153.
4. Yokoe, H., & Anholt, R. R. (1993). Molecular cloning of olfactomedin, an extracellular matrix protein specific to olfactory neuroepithelium. Proceedings of the National Academy of Sciences of the United States of America, 90(10), 4655-4659. (Pubitemid 23148964)
5. Clevers, H. (2006). Wnt/[beta]-catenin signaling in development and disease. Cell, 127(3), 469-480.
6. Croce, J. C., & McClay, D. R. (2008). Evolution of the Wnt pathways. Methods in Molecular Biology, 469, 3-18.
7. Gregorieff, A., Pinto, D., Begthel, H., Destree, O., Kielman, M., & Clevers, H. (2005). Expression pattern of Wnt signaling components in the adult intestine. Gastroenterology, 129(2), 626-638. (Pubitemid 41096648)
8. MacDonald, B. T., Tamai, K., & He, X. (2009). Wnt/beta-catenin signaling: components, mechanisms, and diseases. Developmental Cell, 17(1), 9-26.
9. Johnson, D. H. (2000). Myocilin and glaucoma: a TIGR by the tail? Archives of Ophthalmology, 118(7), 974-978. (Pubitemid 30460638)
10. Resch, Z. T., & Fautsch, M. P. (2009). Glaucoma-associated myocilin: a better understanding but much more to learn. Experimental Eye Research, 88(4), 704-712.
11. Tamm, E. R. (2002). Myocilin and glaucoma: facts and ideas. Progress in Retinal and Eye Research, 21(4), 395-428. (Pubitemid 34874697)
12. Adam, M. F., Belmouden, A., Binisti, P., Brezin, A. P., Valtot, F., Bechetoille, A., et al. (1997). Recurrent mutations in a single exon encoding the evolutionarily conserved olfactomedinhomology domain of tigr in familial open-angle glaucoma. Human Molecular Genetics, 6(12), 2091-2097. (Pubitemid 27477951)
13. Fingert, J. H., Heon, E., Liebmann, J. M., Yamamoto, T., Craig, J. E., Rait, J., et al. (1999). Analysis of myocilin mutations in 1,703 glaucoma patients from five different populations. Human Molecular Genetics, 8(5), 899-905. (Pubitemid 29189058)
14. Fingert, J. H., Stone, E. M., Sheffield, V. C., & Alward, W. L. (2002). Myocilin glaucoma. Survey of Ophthalmology, 47(6), 547-561. (Pubitemid 36009477)
15. Kwon, H. S., Lee, H. S., Ji, Y., Rubin, J. S., & Tomarev, S. I. (2009). Myocilin is a modulator of Wnt signaling. Molecular and Cellular Biology, 29(8), 2139-2154.
16. Kwon, Y. H., Fingert, J. H., Kuehn, M. H., & Alward, W. L. (2009). Primary open-angle glaucoma. The New England Journal of Medicine, 360(11), 1113-1124.
17. Stone, E. M., Fingert, J. H., Alward, W. L., Nguyen, T. D., Polansky, J. R., Sunden, S. L., et al. (1997). Identification of a gene that causes primary open angle glaucoma. Science, 275 (5300), 668-670. (Pubitemid 27061334)
18. Hillier, B. J., & Vacquier, V. D. (2003). Amassin, an olfactomedin protein, mediates the massive intercellular adhesion of sea urchin coelomocytes. The Journal of Cell Biology, 160(4), 597-604. (Pubitemid 36254397)
19. Karavanich, C. A., & Anholt, R. R. (1998). Molecular evolution of olfactomedin. Molecular Biology and Evolution, 15(6), 718-726. (Pubitemid 28240677)
20. Kulkarni, N. H., Karavanich, C. A., Atchley, W. R., & Anholt, R. R. (2000). Characterization and differential expression of a human gene family of olfactomedin-related proteins. Genetical Research, 76(1), 41-50. (Pubitemid 30649601)
21. Loria, P. M., Hodgkin, J., & Hobert, O. (2004). A conserved postsynaptic transmembrane protein affecting neuromuscular signaling in Caenorhabditis elegans. The Journal of Neuroscience, 24(9), 2191-2201. (Pubitemid 38314551)
22. Meyer, E., Aglyamova, G. V., Wang, S., Buchanan-Carter, J., Abrego, D., Colbourne, J. K., et al. (2009). Sequencing and de novo analysis of a coral larval transcriptome using 454 GSFLx. BMC Genomics, 10, 219.
23. Zeng, L. C., Han, Z. G., & Ma, W. J. (2005). Elucidation of subfamily segregation and intramolecular coevolution of the olfactomedin-like proteins by comprehensive phylogenetic analysis and gene expression pattern assessment. FEBS Letters, 579 (25), 5443-5453. (Pubitemid 41455613)
24. Hillier, B. J., Moy, G. W., & Vacquier, V. D. (2007). Diversity of olfactomedin proteins in the sea urchin. Genomics, 89(6), 721-730. (Pubitemid 46719801)
25. Mukhopadhyay, A., Talukdar, S., Bhattacharjee, A., & Ray, K. (2004). Bioinformatic approaches for identification and characterization of olfactomedin related genes with a potential role in pathogenesis of ocular disorders. Molecular Vision, 10, 304-314. (Pubitemid 38628947)
26. van der Flier, L. G., Haegebarth, A., Stange, D. E., van de Wetering, M., & Clevers, H. (2009). Olfm4 is a robust marker for stem cells in human intestine and marks a subset of colorectal cancer cells. Gastroenterology, 137(1), 15-17.
27. van der Flier, L. G., van Gijn, M. E., Hatzis, P., Kujala, P., Haegebarth, A., Stange, D. E., et al. (2009). Transcription factor achaete scute-like 2 controls intestinal stem cell fate. Cell, 136 (5), 903-912.
28. Barker, N., & Clevers, H. (2010). Leucine-rich repeat-containing G-protein-coupled receptors as markers of adult stem cells. Gastroenterology, 138(5), 1681-1696.
29. Barker, N., Ridgway, R. A., van Es, J. H., van de Wetering, M., Begthel, H., van den Born, M., et al. (2009). Crypt stem cells as the cells-of-origin of intestinal cancer. Nature, 457(7229), 608-611.
30. Boman, B. M., & Wicha, M. S. (2008). Cancer stem cells: a step toward the cure. Journal of Clinical Oncology, 26(17), 2795-2799.
31. Dalerba, P., Cho, R. W., & Clarke, M. F. (2007). Cancer stem cells: models and concepts. Annual Review of Medicine, 58, 267-284. (Pubitemid 46706514)
32. Jordan, C. T., Guzman, M. L., & Noble, M. (2006). Cancer stem cells. The New England Journal of Medicine, 355(12), 1253-1261. (Pubitemid 44427449)
33. Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001). Stem cells, cancer, and cancer stem cells. Nature, 414 (6859), 105-111. (Pubitemid 33041634)
34. Rosenbauer, F., Wagner, K., Zhang, P., Knobeloch, K. P., Iwama, A., & Tenen, D. G. (2004). pDP4, a novel glycoprotein secreted by mature granulocytes, is regulated by transcription factor PU.1. Blood, 103(11), 4294-4301. (Pubitemid 38685376)
35. Shinozaki, S., Nakamura, T., Iimura, M., Kato, Y., Iizuka, B., Kobayashi, M., et al. (2001). Upregulation of Reg 1alpha and GW112 in the epithelium of inflamed colonic mucosa. Gut, 48 (5), 623-629. (Pubitemid 32378580)
36. Zhang, J., Liu, W. L., Tang, D. C., Chen, L., Wang, M., Pack, S. D., et al. (2002). Identification and characterization of a novel member of olfactomedin-related protein family, hGC-1, expressed during myeloid lineage development. Gene, 283(1- 2), 83-93. (Pubitemid 34178512)
37. Zhang, X., Huang, Q., Yang, Z., Li, Y., & Li, C. Y. (2004). Gw112, a novel antiapoptotic protein that promotes tumor growth. Cancer Research, 64(7), 2474-2481. (Pubitemid 38523902)
38. Liu, W., Chen, L., Zhu, J., & Rodgers, G. P. (2006). The glycoprotein hGC-1 binds to cadherin and lectins. Experimental Cell Research, 312(10), 1785-1797. (Pubitemid 44218717)
39. Fautsch, M. P., & Johnson, D. H. (2001). Characterization of myocilin-myocilin interactions. Invest Ophthalmol Vis Sci, 42 (10), 2324-2331. (Pubitemid 32848862)
40. Chin, K. L., Aerbajinai, W., Zhu, J., Drew, L., Chen, L., Liu, W., et al. (2008). The regulation of OLFM4 expression in myeloid precursor cells relies on NF-kappaB transcription factor. British Journal Haematology, 143(3), 421-432.
41. Kim, K. K., Park, K. S., Song, S. B., & Kim, K. E. (2010). Up regulation of GW112 gene by NF kappaB promotes an antiapoptotic property in gastric cancer cells. Molecular Carcinogenesis, 49(3), 259-270.
42. Ayoubi, T. A., & Van De Ven, W. J. (1996). Regulation of gene expression by alternative promoters. The FASEB Journal, 10(4), 453-460. (Pubitemid 26120320)
43. Baek, D., Davis, C., Ewing, B., Gordon, D., & Green, P. (2007). Characterization and predictive discovery of evolutionarily conserved mammalian alternative promoters. Genome Research, 17(2), 145-155. (Pubitemid 46220759)
44. Davuluri, R. V., Suzuki, Y., Sugano, S., Plass, C., & Huang, T. H. (2008). The functional consequences of alternative promoter use in mammalian genomes. Trends in Genetics, 24(4), 167-177.
45. Burke, T. W., & Kadonaga, J. T. (1997). The downstream core promoter element, DPE, is conserved from Drosophila to humans and is recognized by TAFII60 of Drosophila. Genes & Development, 11(22), 3020-3031. (Pubitemid 27508512)
46. Deng, W., & Roberts, S. G. (2005). A core promoter element downstream of the TATA box that is recognized by TFIIB. Genes & Development, 19(20), 2418-2423. (Pubitemid 41483689)
47. Lee, D. H., Gershenzon, N., Gupta, M., Ioshikhes, I. P., Reinberg, D., & Lewis, B. A. (2005). Functional characterization of core promoter elements: the downstream core element is recognized by TAF1. Molecular and Cellular Biology, 25(21), 9674-9686. (Pubitemid 41507864)
48. Smale, S. T., & Kadonaga, J. T. (2003). The RNA polymerase II core promoter. Annual Review of Biochemistry, 72, 449-479. (Pubitemid 36930452)
49. Liu, W., Yan, M., Liu, Y., Wang, R., Li, C., Deng, C., et al. (2010). Olfactomedin 4 down-regulates innate immunity against Helicobacter pylori infection. Proceedings of the National Academy of Sciences of the United States of America, 107(24), 11056-11061.
50. Finkel, T. (2000). Redox-dependent signal transduction. FEBS Letters, 476(1-2), 52-54. (Pubitemid 30394649)
51. Halliwell, B. (2003). Oxidative stress in cell culture: an underappreciated problem? FEBS Letters, 540(1-3), 3-6. (Pubitemid 36398024)
52. Torres, M., & Forman, H. J. (2003). Redox signaling and the map kinase pathways. Biofactors, 17(1-4), 287-296. (Pubitemid 37267162)
53. Duarte, R. F., & Frank, D. A. (2000). SCF and G-CSF lead to the synergistic induction of proliferation and gene expression through complementary signaling pathways. Blood, 96(10), 3422-3430.
54. Meplan, C., Richard, M. J., & Hainaut, P. (2000). Redox signalling and transition metals in the control of the p53 pathway. Biochemical Pharmacology, 59(1), 25-33.
55. Rahman, I., Marwick, J., & Kirkham, P. (2004). Redox modulation of chromatin remodeling: impact on histone acetylation and deacetylation, NF-kappaB and pro-inflammatory gene expression. Biochemical Pharmacology, 68(6), 1255-1267. (Pubitemid 39094292)
56. Rao, G. N., Katki, K. A., Madamanchi, N. R., Wu, Y., & Birrer, M. J. (1999). JunB forms the majority of the AP-1 complex and is a target for redox regulation by receptor tyrosine kinase and G protein-coupled receptor agonists in smooth muscle cells. The Journal of Biological Chemistry, 274(9), 6003-6010. (Pubitemid 29109261)
57. Renner, F., & Schmitz, M. L. (2009). Autoregulatory feedback loops terminating the NF-kappaB response. Trends in Biochemical Sciences, 34(3), 128-135.
58. Eichbaum, Q. G., Iyer, R., Raveh, D. P., Mathieu, C., & Ezekowitz, R. A. (1994). Restriction of interferon gamma responsiveness and basal expression of the myeloid human Fc gamma R1b gene is mediated by a functional PU.1 site and a transcription initiator consensus. The Journal of Experimental Medicine, 179(6), 1985-1996. (Pubitemid 24155678)
59. Hagemeier, C., Bannister, A. J., Cook, A., & Kouzarides, T. (1993). The activation domain of transcription factor PU.1 binds the retinoblastoma (RB) protein and the transcription factor TFIID in vitro: Rb shows sequence similarity to TFIID and TFIIB. Proceedings of the National Academy of Sciences of the United States of America, 90(4), 1580-1584. (Pubitemid 23058217)
60. Tenen, D. G., Hromas, R., Licht, J. D., & Zhang, D. E. (1997). Transcription factors, normal myeloid development, and leukemia. Blood, 90(2), 489-519. (Pubitemid 27299089)
61. Weintraub, S. J., Chow, K. N., Luo, R. X., Zhang, S. H., He, S., & Dean, D. C. (1995). Mechanism of active transcriptional repression by the retinoblastoma protein. Nature, 375(6534), 812-815.
62. Inoue, J., Gohda, J., Akiyama, T., & Semba, K. (2007). Nfkappab activation in development and progression of cancer. Cancer Science, 98(3), 268-274. (Pubitemid 46195594)
63. Van Waes, C. (2007). Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clinical Cancer Research, 13 (4), 1076-1082. (Pubitemid 46424045)
64. Shaulian, E., & Karin, M. (2001). Ap-1 in cell proliferation and survival. Oncogene, 20(19), 2390-2400. (Pubitemid 32531297)
65. Vesely, P. W., Staber, P. B., Hoefler, G., & Kenner, L. (2009). Translational regulation mechanisms of AP-1 proteins. Mutation Research, 682(1), 7-12.
66. Gupta, P., Gurudutta, G. U., Verma, Y. K., Kishore, V., Gulati, S., Sharma, R. K., et al. (2006). PU. 1: an ETS family transcription factor that regulates leukemogenesis besides normal hematopoiesis. Stem Cells and Development, 15(4), 609-617. (Pubitemid 44701179)
67. Kastner, P., & Chan, S. (2008). PU. 1: a crucial and versatile player in hematopoiesis and leukemia. The International Journal of Biochemistry & Cell Biology, 40(1), 22-27. (Pubitemid 350052657)
68. Baud, V., & Karin, M. (2009). Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nature Reviews. Drug Discovery, 8(1), 33-40.
69. Choe, K. S., Ujhelly, O., Wontakal, S. N., & Skoultchi, A. I. (2010). PU. 1 directly regulates cdk6 gene expression, linking the cell proliferation and differentiation programs in erythroid cells. The Journal of Biological Chemistry, 285(5), 3044-3052.
70. Eferl, R., & Wagner, E. F. (2003). AP-1: a double-edged sword in tumorigenesis. Nature Reviews. Cancer, 3(11), 859-868. (Pubitemid 37383716)
71. Lee, C. H., Jeon, Y. T., Kim, S. H., & Song, Y. S. (2007). NfkappaB as a potential molecular target for cancer therapy. Biofactors, 29(1), 19-35. (Pubitemid 46985299)
72. Verde, P., Casalino, L., Talotta, F., Yaniv, M., & Weitzman, J. B. (2007). Deciphering AP-1 function in tumorigenesis: fraternizing on target promoters. Cell Cycle, 6(21), 2633-2639. (Pubitemid 350224046)
73. Bonadies, N., Neururer, C., Steege, A., Vallabhapurapu, S., Pabst, T., & Mueller, B. U. (2010). PU. 1 is regulated by NFkappaB through a novel binding site in a 17 kb upstream enhancer element. Oncogene, 29(7), 1062-1072.
74. Basseres, D. S., & Baldwin, A. S. (2006). Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene, 25(51), 6817-6830. (Pubitemid 44657854)
75. Fan, X. M., Wong, B. C., Wang, W. P., Zhou, X. M., Cho, C. H., Yuen, S. T., et al. (2001). Inhibition of proteasome function induced apoptosis in gastric cancer. International Journal of Cancer, 93(4), 481-488. (Pubitemid 32701406)
76. Nakanishi, C., & Toi, M. (2005). Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nature Reviews. Cancer, 5(4), 297-309. (Pubitemid 40488635)
77. Nakshatri, H., Bhat-Nakshatri, P., Martin, D. A., Goulet, R. J., Jr., & Sledge, G. W., Jr. (1997). Constitutive activation of NFkappaB during progression of breast cancer to hormoneindependent growth. Molecular and Cellular Biology, 17(7), 3629-3639. (Pubitemid 27281838)
78. Pacifico, F., & Leonardi, A. (2006). NF-kappaB in solid tumors. Biochemical Pharmacology, 72(9), 1142-1152.
79. Bernard, D., Monte, D., Vandenbunder, B., & Abbadie, C. (2002). The c-Rel transcription factor can both induce and inhibit apoptosis in the same cells via the upregulation of MnSOD. Oncogene, 21(28), 4392-4402. (Pubitemid 34774842)
80. Kaltschmidt, B., Kaltschmidt, C., Hofmann, T. G., Hehner, S. P., Droge, W., & Schmitz, M. L. (2000). The pro- or anti-apoptotic function of NF-kappaB is determined by the nature of the apoptotic stimulus. European Journal of Biochemistry, 267(12), 3828-3835. (Pubitemid 30423046)
81. Sheehy, A. M., & Schlissel, M. S. (1999). Overexpression of RelA causes G1 arrest and apoptosis in a pro-B cell line. The Journal of Biological Chemistry, 274(13), 8708-8716. (Pubitemid 29164667)
82. Tarabin, V., & Schwaninger, M. (2004). The role of NF-kappaB in 6-hydroxydopamine- and TNFalpha-induced apoptosis of PC12 cells. Naunyn-Schmiedebergs Archives of Pharmacology, 369(6), 563-569. (Pubitemid 38823988)
83. Chen, F., & Castranova, V. (2007). Nuclear factor-kappaB, an unappreciated tumor suppressor. Cancer Research, 67(23), 11093-11098. (Pubitemid 350248529)
84. Karin, M. (2006). Nuclear factor-kappaB in cancer development and progression. Nature, 441(7092), 431-436. (Pubitemid 44050137)
85. Liu, W., Liu, Y., Zhu, J., Wright, E., Ding, I., & Rodgers, G. P. (2008). Reduced hGC-1 protein expression is associated with malignant progression of colon carcinoma. Clinical Cancer Research, 14(4), 1041-1049. (Pubitemid 351302549)
86. Conrotto, P., Roesli, C., Rybak, J., Kischel, P., Waltregny, D., Neri, D., et al. (2008). Identification of new accessible tumor antigens in human colon cancer by ex vivo protein biotinylation and comparative mass spectrometry analysis. International Journal of Cancer, 123(12), 2856-2864.
87. Oue, N., Sentani, K., Noguchi, T., Ohara, S., Sakamoto, N., Hayashi, T., et al. (2009). Serum olfactomedin 4 (GW112, hGC- 1) in combination with Reg IV is a highly sensitive biomarker for gastric cancer patients. International Journal of Cancer, 125(10), 2383-2392.
88. Liu, W., Zhu, J., Cao, L., & Rodgers, G. P. (2007). Expression of hGC-1 is correlated with differentiation of gastric carcinoma. Histopathology, 51(2), 157-165. (Pubitemid 47084003)
89. Duband, J. L., Dufour, S., Hatta, K., Takeichi, M., Edelman, G. M., & Thiery, J. P. (1987). Adhesion molecules during somitogenesis in the avian embryo. The Journal of Cell Biology, 104 (5), 1361-1374. (Pubitemid 17084495)
90. Nelson, W. J. (2008). Regulation of cell-cell adhesion by the cadherin-catenin complex. Biochemical Society Transactions, 36 (Pt 2), 149-155. (Pubitemid 351570584)
91. Takeichi, M. (1991). Cadherin cell adhesion receptors as a morphogenetic regulator. Science, 251(5000), 1451-1455. (Pubitemid 121000430)
92. Takeichi, M. (1995). Morphogenetic roles of classic cadherins. Current Opinion in Cell Biology, 7(5), 619-627.
93. Makrilia, N., Kollias, A., Manolopoulos, L., & Syrigos, K. (2009). Cell adhesion molecules: role and clinical significance in cancer. Cancer Investigation, 27(10), 1023-1037.
94. Paschos, K. A., Canovas, D., & Bird, N. C. (2009). The role of cell adhesion molecules in the progression of colorectal cancer and the development of liver metastasis. Cellular Signalling, 21 (5), 665-674.
95. Cavallaro, U., & Christofori, G. (2004). Cell adhesion and signalling by cadherins and Ig-CAMS in cancer. Nature Reviews. Cancer, 4(2), 118-132. (Pubitemid 38198740)
96. Angell, J. E., Lindner, D. J., Shapiro, P. S., Hofmann, E. R., & Kalvakolanu, D. V. (2000). Identification of GRIM-19, a novel cell death-regulatory gene induced by the interferon-beta and retinoic acid combination, using a genetic approach. The Journal of Biological Chemistry, 275(43), 33416-33426.
97. Chidambaram, N. V., Angell, J. E., Ling, W., Hofmann, E. R., & Kalvakolanu, D. V. (2000). Chromosomal localization of human GRIM-19, a novel IFN-beta and retinoic acid-activated regulator of cell death. Journal of Interferon & Cytokine Research, 20(7), 661-665. (Pubitemid 30481719)
98. Fearnley, I. M., Carroll, J., Shannon, R. J., Runswick, M. J., Walker, J. E., & Hirst, J. (2001). GRIM-19, a cell death regulatory gene product, is a subunit of bovine mitochondrial NADH:ubiquinone oxidoreductase (complex I). The Journal of Biological Chemistry, 276(42), 38345-38348.
99. Lufei, C., Ma, J., Huang, G., Zhang, T., Novotny-Diermayr, V., Ong, C. T., et al. (2003). GRIM-19, a death-regulatory gene product, suppresses Stat3 activity via functional interaction. The EMBO Journal, 22(6), 1325-1335. (Pubitemid 36362696)
100. Seo, T., Lee, D., Shim, Y. S., Angell, J. E., Chidambaram, N. V., Kalvakolanu, D. V., et al. (2002). Viral interferon regulatory factor 1 of Kaposi's sarcoma-associated herpesvirus interacts with a cell death regulator, GRIM19, and inhibits interferon/ retinoic acid-induced cell death. Journal of Virology, 76(17), 8797-8807. (Pubitemid 34864075)
101. Liu, X., Kim, C. N., Yang, J., Jemmerson, R., & Wang, X. (1996). Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell, 86(1), 147-157. (Pubitemid 26256586)
102. Luo, X., Budihardjo, I., Zou, H., Slaughter, C., & Wang, X. (1998). Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell, 94(4), 481-490. (Pubitemid 28391864)
103. Yang, J., Liu, X., Bhalla, K., Kim, C.N., Ibrado, A.M., Cai, J., et al. (1997). Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science, 275(5303), 1129-1132. (Pubitemid 27097312)
104. Yin, X. M., Wang, K., Gross, A., Zhao, Y., Zinkel, S., Klocke, B., et al. (1999). Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature, 400(6747), 886-891. (Pubitemid 29406726)
105. Maytin, E.V., Ubeda,M., Lin, J. C.,&Habener, J. F. (2001). Stressinducible transcription factor CHOP/GADD153 induces apoptosis in mammalian cells via p38 kinase-dependent and -independent mechanisms. Experimental Cell Research, 267(2), 193-204. (Pubitemid 32635013)
106. Polyak, K., Xia, Y., Zweier, J. L., Kinzler, K. W., & Vogelstein, B. (1997). A model for p53-induced apoptosis. Nature, 389 (6648), 300-305. (Pubitemid 27406646)
107. Sun, X., Majumder, P., Shioya, H., Wu, F., Kumar, S., Weichselbaum, R., et al. (2000). Activation of the cytoplasmic c-Abl tyrosine kinase by reactive oxygen species. The Journal of Biological Chemistry, 275(23), 17237-17240. (Pubitemid 30430754)
108. Kobayashi, D., Koshida, S., Moriai, R., Tsuji, N., & Watanabe, N. (2007). Olfactomedin 4 promotes s-phase transition in proliferation of pancreatic cancer cells. Cancer Science, 98(3), 334-340. (Pubitemid 46195603)
109. Koshida, S., Kobayashi, D., Moriai, R., Tsuji, N., & Watanabe, N. (2007). Specific overexpression of OLFM4(GW112/hGC-1) mrna in colon, breast and lung cancer tissues detected using quantitative analysis. Cancer Science, 98(3), 315-320. (Pubitemid 46195600)
110. Semenza, G. L. (2000). Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Critical Reviews in Biochemistry and Molecular Biology, 35(2), 71-103. (Pubitemid 30253678)
111. Tannock, I. F., & Rotin, D. (1989). Acid pH in tumors and its potential for therapeutic exploitation. Cancer Research, 49(16), 4373-4384. (Pubitemid 19208329)
112. Stratford, I. J., Adams, G. E., Bremner, J. C., Cole, S., Edwards, H. S., Robertson, N., et al. (1994). Manipulation and exploitation of the tumour environment for therapeutic benefit. International Journal of Radiation Biology, 65(1), 85-94. (Pubitemid 24063534)
113. Xiao, Z., Xue, J., Sowin, T. J., Rosenberg, S. H., & Zhang, H. (2005). A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation. Oncogene, 24(8), 1403-1411. (Pubitemid 40343120)
114. Liang, J., & Slingerland, J. M. (2003). Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle, 2 (4), 339-345.
115. Asanuma, H., Torigoe, T., Kamiguchi, K., Hirohashi, Y., Ohmura, T., Hirata, K., et al. (2005). Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells. Cancer Research, 65(23), 11018-11025. (Pubitemid 41713372)
116. Beltrami, E., Plescia, J., Wilkinson, J. C., Duckett, C. S., & Altieri, D. C. (2004). Acute ablation of survivin uncovers p53- dependent mitotic checkpoint functions and control of mitochondrial apoptosis. The Journal of Biological Chemistry, 279(3), 2077-2084. (Pubitemid 38084480)
117. Hu, P., Han, Z., Couvillon, A. D., & Exton, J. H. (2004). Critical role of endogenous Akt/IAPS and MEK1/ERK pathways in counteracting endoplasmic reticulum stress-induced cell death. The Journal of Biological Chemistry, 279(47), 49420-49429. (Pubitemid 39625828)
118. Johnson, N. C., Dan, H. C., Cheng, J. Q., & Kruk, P. A. (2004). BRCA1 185delAG mutation inhibits AKT-dependent, IAPmediated caspase 3 inactivation in human ovarian surface epithelial cells. Experimental Cell Research, 298(1), 9-16. (Pubitemid 38887302)
119. Li, F., Ambrosini, G., Chu, E. Y., Plescia, J., Tognin, S., Marchisio, P. C., et al. (1998). Control of apoptosis and mitotic spindle checkpoint by survivin. Nature, 396(6711), 580-584. (Pubitemid 28563719)
120. Samuel, T., Okada, K., Hyer, M., Welsh, K., Zapata, J. M., & Reed, J. C. (2005). CIAP1 localizes to the nuclear compartment and modulates the cell cycle. Cancer Research, 65(1), 210-218. (Pubitemid 40070812)
121. Sommer, K.W., Schamberger, C. J., Schmidt, G. E., Sasgary, S., & Cerni, C. (2003). Inhibitor of apoptosis protein (IAP) survivin is upregulated by oncogenic c-H-Ras. Oncogene, 22(27), 4266-4280. (Pubitemid 36876247)
122. Nakaya, N., Lee, H. S., Takada, Y., Tzchori, I., & Tomarev, S. I. (2008). Zebrafish olfactomedin 1 regulates retinal axon elongation in vivo and is a modulator of Wnt signaling pathway. The Journal of Neuroscience, 28(31), 7900-7910.
123. Logan, C. Y., & Nusse, R. (2004). The Wnt signaling pathway in development and disease. Annual Review of Cell and Developmental Biology, 20, 781-810. (Pubitemid 39488658)
124. van Amerongen, R., & Nusse, R. (2009). Towards an integrated view of Wnt signaling in development. Development, 136(19), 3205-3214.
125. Mannick, E. E., Schurr, J. R., Zapata, A., Lentz, J. J., Gastanaduy, M., Cote, R. L., et al. (2004). Gene expression in gastric biopsies from patients infected with Helicobacter pylori. Scandinavian Journal of Gastroenterology, 39(12), 1192-1200. (Pubitemid 39656833)
126. Aung, P. P., Oue, N., Mitani, Y., Nakayama, H., Yoshida, K., Noguchi, T., et al. (2006). Systematic search for gastric cancerspecific genes based on sage data: melanoma inhibitory activity and matrix metalloproteinase-10 are novel prognostic factors in patients with gastric cancer. Oncogene, 25(17), 2546-2557.
127. Oue, N., Aung, P. P., Mitani, Y., Kuniyasu, H., Nakayama, H., & Yasui, W. (2005). Genes involved in invasion and metastasis of gastric cancer identified by array-based hybridization and serial analysis of gene expression. Oncology, 69(Suppl 1), 17-22. (Pubitemid 41433537)
128. Yasui, W., Oue, N., Aung, P. P., Matsumura, S., Shutoh, M., & Nakayama, H. (2005). Molecular-pathological prognostic factors of gastric cancer: a review. Gastric Cancer, 8(2), 86-94. (Pubitemid 40655517)
129. Grutzmann, R., Pilarsky, C., Staub, E., Schmitt, A. O., Foerder, M., Specht, T., et al. (2003). Systematic isolation of genes differentially expressed in normal and cancerous tissue of the pancreas. Pancreatology, 3(2), 169-178. (Pubitemid 36577080)
130. Wentzensen, N., Wilz, B., Findeisen, P., Wagner, R., Dippold, W., von Knebel Doeberitz, M., et al. (2004). Identification of differentially expressed genes in colorectal adenoma compared to normal tissue by suppression subtractive hybridization. International Journal of Oncology, 24(4), 987-994.
131. Li, S. R., Dorudi, S., & Bustin, S. A. (2003). Identification of differentially expressed genes associated with colorectal cancer liver metastasis. European Surgical Research, 35(4), 327-336. (Pubitemid 36736900)
132. Barker, N., & Clevers, H. (2007). Tracking down the stem cells of the intestine: strategies to identify adult stem cells. Gastroenterology, 133(6), 1755-1760. (Pubitemid 350180827)
133. Barker, N., van Es, J. H., Kuipers, J., Kujala, P., van den Born, M., Cozijnsen, M., et al. (2007). Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature, 449 (7165), 1003-1007. (Pubitemid 350014593)
134. Barker, N., van de Wetering, M., & Clevers, H. (2008). The intestinal stem cell. Genes & Development, 22(14), 1856-1864. (Pubitemid 352008634)
135. Potten, C. S. (1977). Extreme sensitivity of some intestinal crypt cells to X and gamma irradiation. Nature, 269(5628), 518-521. (Pubitemid 8245145)
136. Potten, C. S., Kovacs, L., & Hamilton, E. (1974). Continuous labelling studies on mouse skin and intestine. Cell and Tissue Kinetics, 7(3), 271-283.
137. Sangiorgi, E., & Capecchi, M. R. (2008). Bmi1 is expressed in vivo in intestinal stem cells. Nature Genetics, 40(7), 915-920. (Pubitemid 351913652)
138. Kosinski, C., Li, V. S., Chan, A. S., Zhang, J., Ho, C., Tsui, W. Y., et al. (2007). Gene expression patterns of human colon tops and basal crypts and bmp antagonists as intestinal stem cell niche factors. Proceedings of the National Academy of Sciences of the United States of America, 104(39), 15418-15423. (Pubitemid 47502932)
139. Dalerba, P., Dylla, S. J., Park, I. K., Liu, R., Wang, X., Cho, R. W., et al. (2007). Phenotypic characterization of human colorectal cancer stem cells. Proceedings of the National Academy of Sciences of the United States of America, 104(24), 10158-10163. (Pubitemid 47175279)
140. O'Brien, C. A., Pollett, A., Gallinger, S., & Dick, J. E. (2007). A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature, 445(7123), 106-110. (Pubitemid 46067310)
141. Ricci-Vitiani, L., Lombardi, D. G., Pilozzi, E., Biffoni, M., Todaro, M., Peschle, C., et al. (2007). Identification and expansion of human colon-cancer-initiating cells. Nature, 445 (7123), 111-115. (Pubitemid 46067311)
142. Vermeulen, L., Todaro, M., de Sousa Mello, F., Sprick, M. R., Kemper, K., Perez Alea, M., et al. (2008). Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proceedings of the National Academy of Sciences of the United States of America, 105(36), 13427-13432.